Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
AssigneeFoundation Medicine, Inc.
InventorsMeagan Kathleen MONTESION, Lee Alan ALBACKER, Karthikeyan MURUGESAN
Life of this patent
Estimating the term…
Abstract
Provided herein are methods related to detecting loss of heterozygosity (LOH) of one or more human leukocyte antigen (HLA) genes and/or tumor mutational burden (TMB), as well as methods of treatment and uses related thereto. Detection of LOH of one or more HLA genes and/or TMB can be used to identify individuals that may benefit from treatment with an immune checkpoint inhibitor.
Claims36
1-8. (canceled)
A method of treating or delaying progression of a squamous cell cancer or a NSCLC, comprising:
- (a) acquiring knowledge of:
- (i) a somatic LOH of one or more HLA-I genes, or
- (ii) a somatic LOH of one or more HLA-I genes and a high TMB,
- in a sample from an individual having a squamous cell cancer or a NSCLC;
- and
- (b) responsive to said knowledge, administering to the individual an effective amount of a treatment that comprises an immune checkpoint inhibitor.
A method of treating or delaying progression of a squamous cell cancer or a NSCLC, comprising,
- responsive to acquiring knowledge of:
- (i) a somatic LOH of one or more HLA-I genes, or
- (ii) a somatic LOH of one or more HLA-I genes and a high TMB,
- in a sample from an individual having a squamous cell cancer or a NSCLC,
- administering to the individual an effective amount of a treatment that comprises an immune checkpoint inhibitor.
(canceled)
A method of treating or delaying progression of a squamous cell cancer or a NSCLC, comprising:
- (a) detecting in a sample from an individual having a squamous cell cancer or a NSCLC:
- (i) a somatic LOH of one or more HLA-I genes, or
- (ii) a somatic LOH of one or more HLA-I genes and a high TMB;
- and
- (b) administering to the individual an effective amount of a treatment that comprises an immune checkpoint inhibitor.
13-14. (canceled)
(canceled)
18-20. (canceled)
22-24. (canceled)
(canceled)
28-31. (canceled)
34-35. (canceled)
37-39. (canceled)
41-43. (canceled)
46-47. (canceled)
49-57. (canceled)
59-71. (canceled)
75-80. (canceled)
82-99. (canceled)
Dependencies are inferred from the claim text.